Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of “Moderate Buy” by Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $9.75.

REPL has been the subject of several research analyst reports. Cantor Fitzgerald upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating in a report on Wednesday, July 30th. HC Wainwright raised shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Monday, October 27th. Leerink Partnrs raised Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price on the stock in a research report on Monday, October 20th. Finally, Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and upped their target price for the company from $4.00 to $18.00 in a research report on Monday, October 20th.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 5,208 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total transaction of $47,392.80. Following the completion of the sale, the insider owned 123,088 shares in the company, valued at $1,120,100.80. This represents a 4.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,248 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $65,956.80. Following the transaction, the insider directly owned 139,685 shares in the company, valued at $1,271,133.50. The trade was a 4.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently made changes to their positions in REPL. Goldman Sachs Group Inc. raised its position in Replimune Group by 20.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after buying an additional 119,145 shares during the last quarter. Exome Asset Management LLC raised its holdings in Replimune Group by 438.6% during the first quarter. Exome Asset Management LLC now owns 294,846 shares of the company’s stock worth $2,875,000 after purchasing an additional 240,108 shares in the last quarter. Nuveen LLC acquired a new stake in Replimune Group in the first quarter valued at about $6,546,000. Deutsche Bank AG lifted its holdings in shares of Replimune Group by 0.4% in the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company’s stock valued at $5,496,000 after buying an additional 2,140 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Replimune Group by 8.4% in the first quarter. Bank of New York Mellon Corp now owns 189,177 shares of the company’s stock valued at $1,844,000 after buying an additional 14,659 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Up 2.1%

NASDAQ:REPL opened at $9.20 on Friday. Replimune Group has a 1 year low of $2.68 and a 1 year high of $17.00. The stock has a market cap of $721.65 million, a P/E ratio of -2.66 and a beta of 0.80. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.31 and a current ratio of 6.31. The stock has a 50-day simple moving average of $6.75 and a 200-day simple moving average of $7.40.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). As a group, analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.